Harry Welten
Director of Finance/CFO at AFFIMED N.V.
Net worth: 73 200 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deborah S. Geraghty | F | - |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Christian Brühlmann | M | - |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Adolf Hoess | M | 62 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 14 years |
| Thomas O. Hecht | M | 73 |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 21 years |
| Ralph Schiess | M | 46 |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Joost de Bruijn | M | 58 | 7 years | |
| Ulrich Grau | M | 75 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 9 years |
| Ferdinand Verdonck | M | 81 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 10 years |
| Jeffrey A. Hubbell | M | - |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | 9 years |
| Anna Sumeray | F | - |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland.
Virometix AG
 Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | 3 years |
| Bernhard R. M. Ehmer | M | 69 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 8 years |
| Annalisa Jenkins | M | 58 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 years |
| Wolfgang Fischer | M | 60 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 7 years |
| Mathieu Simon | M | 68 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 6 years |
| Scott P. Bruder | M | 62 | 6 years | |
| Mary Beth Sandin | F | - | - | |
| Constanze Ulmer-Eilfort | M | 62 | 1 years | |
| Uta Kemmerich-Keil | F | 58 | 3 years | |
| Andreas Harstrick | M | 63 | 4 years | |
| Ruedi Aebersold | M | - |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Michael Clayman | M | 72 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Clemens A. van Blitterswijk | M | 67 | 7 years | |
| Oliver Walker | M | 55 | 6 years | |
| Thomas Cerny | M | 72 |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | - |
| Thomas Woiwode | M | 52 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Patrick Paul Mc Ilvenny | M | - |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | - |
| Thomas Dyrberg | M | 69 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Patricia Allen | F | 62 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Axel Polack | M | 67 |
Virometix AG
Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | - |
| Denise Mueller | F | 55 | 8 years | |
| Alexander Fudukidis | M | - | 4 years | |
| Susanne Hering | F | - | 9 years | |
| Dhavalkumar Patel | M | 63 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Leanna Caron | F | 56 | 8 years | |
| Jan Henrik ter Meulen | M | 61 |
Virometix AG
Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | - |
| Philippe Saudan | M | 57 | 8 years | |
| Laura Brass | M | - |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | - |
| Vincent Serra | M | 55 |
BioSupport AG
| - |
| Susanne Schultz-Hector | M | - |
Virometix AG
Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | - |
| Matthias Währen | M | 71 |
HBM Fondation
| 6 years |
| Florence Barrère de Groot | M | - | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Itin | M | 59 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 7 years |
| Didier Cowling | M | 59 | 18 years | |
| Wolfgang Renner | M | 57 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 16 years |
| Khalid Islam | M | 67 |
Arpida AG
 Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 9 years |
| Martin F. Bachmann | M | 57 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 12 years |
| Michael Grau | M | 62 | 5 years | |
| Philipp Mueller | M | 71 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 10 years |
| Gerhard Ries | M | 55 | 3 years | |
| Wilhelm Krek | M | - |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | - |
| Nicholas Draeger | M | 58 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | - |
| Giacomo di Nepi | M | 72 | 2 years | |
| Ivan Cohen-Tanugi | M | - | - | |
| Jakob Schlapbach | M | 73 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 12 years |
| Subhasis Roy | M | 55 |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | 3 years |
| Matthias Alder | M | 59 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 1 years |
| Jason M. Hannon | M | 52 | - | |
| Arndt Justus Georg Schottelius | M | 58 | 4 years | |
| Paul Verbraeken | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Jean-Yves Le Cotonnec | M | 75 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 8 years |
| André L. Lamotte | M | 75 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Cheryl Lassen | M | - |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | - |
| Helge Lubenow | M | 56 |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | - |
| Bernhard Erni | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Yamo Deniz | M | 60 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 1 years |
| Jason Schense | M | 52 | 17 years | |
| Angus Smith | M | 41 | 3 years | |
| Ivan Kompis | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Hans Fünfschilling | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Dieter Gillessen | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 years |
| Othmar T. Vock | M | 81 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 5 years |
| Paul Brooke | M | 77 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 2 years |
| Kurt von Emster | M | 56 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 3 years |
| Vincent Ossipow | M | 55 | 1 years | |
| Arthur M. Krieg | M | 66 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 2 years |
| Jörg Neermann | M | 57 | 2 years | |
| Mark H. Richmond | M | 93 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 12 years |
| Joseph Anderson | M | 65 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 4 years |
| Matthias Staehelin | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Elmar Schnee | M | 65 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Michel Lucien Pettigrew | M | 71 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Frank-Jan van der Velden | M | 65 | 1 years | |
| Jürgen Raths | M | 68 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 1 years |
| John Berriman | M | 76 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | - |
| Jon Bondebjerg | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 3 years |
| Virginia Jamieson | M | 71 | 2 years | |
| Charlie Campion | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 63 | 72.41% |
| Germany | 17 | 19.54% |
| United States | 8 | 9.20% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Harry Welten
- Personal Network
